A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis

NCT04612699 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-Severe Plaque Psoriasis

Interventions

DRUG: Jaktinib
DRUG: Placebo

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd